MEKAWIRE
United States

Remedy Robotics

San Francisco developer of the N1, an AI-enabled robotic system for on-site, remote and autonomous endovascular procedures (investigational).

Remedy Robotics has raised $62M across 1 disclosed round since Nov 16, 2026; the latest round, Series B, was announced on Nov 16, 2026. Data as of Nov 17, 2026.

Headquartered in San Francisco, United States.

Latest from MEKAWIRE

About

Remedy Robotics develops the N1 System, a robotic platform and software suite for catheter-based (endovascular) procedures in stroke and other cardiovascular emergencies. The company says the N1 analyses preoperative imaging with machine learning, simulates cases in advance, registers 3D and 2D images in real time and is designed for on-site, remote or autonomous operation. The N1 is under development and not available for sale or clinical use in any jurisdiction.

In November 2026 the company raised a USD 62 million Series B led by DCVC.

Key stats
Latest funding
$62M Series B
Total funding
$62M
Latest valuation
—
Founded
—
Country
United States
Company facts
Headquarters
San Francisco
Latest roundsAll rounds
Recent newsAll news

Related companies